Dr. Joseph Biederman is currently receiving research support from the following sources: Bristol-Myers Squibb, Eli Lilly and Company, Janssen, L.P., Ortho-McNeil, Inc., Otsuka, Shire, NIMH, and the National Institute of Child Health and Human Development Dr. Joseph Biederman is currently a consultant/advisory board member for the following pharmaceutical companies: Janssen, L.P., Ortho-McNeil, Inc., Novartis, and Shire. Dr. Joseph Biederman is currently a speaker for the following speaker's bureaus: Janssen, Ortho-McNeil, Inc., Novartis, Shire, and UCB Pharma, Inc. In previous years, Dr. Joseph Biederman received research support, consultation fees, or speaker's fees for/from the following additional sources: Abbott, AstraZeneca, Celltech, Cephalon, Eli Lilly and Company, Esai, Forest, GlaxoSmithKline, Gliatech Inc., NARSAD, New River Behavioral HealthCare, the National Institute on Drug Abuse, Novartis, Noven, Neurosearch, Pfizer, Pharmacia, The Prechter Foundation, The Stanley Foundation, and Wyeth.

"My interests are solely in the advancement of medical treatment through rigorous and objective study,” and he said he took conflict-of-interest policies “very seriously.”